Seres Therapeutics, Inc. (NASDAQ: MCRB) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
The Athlete's Edge: How One Biotech Startup Is Mining Elite Athletes' Gut Bacteria To Create Next-Gen Probiotics [Forbes]
Seres Therapeutics, Inc. (NASDAQ: MCRB) had its "buy" rating re-affirmed by analysts at Canaccord Genuity Group Inc.. They now have a $10.00 price target on the stock.
Seres Therapeutics Inc (MCRB) Q3 2024 Earnings Call Highlights: Strategic Moves and Clinical ... [Yahoo! Finance]
Seres Therapeutics, Inc. (NASDAQ: MCRB) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $1.25 price target on the stock.